Reciprocal regulation of PCGEM1 and miR-145 promote proliferation of LNCaP prostate cancer cells

Journal of Experimental & Clinical Cancer Research

Yu-Guang Li¹  Yu Bing Lv¹  Li Wang¹  Ze-Ping Han¹  Jing-zhi Zhang²  Jin-Hua He¹ 

[1] Department of Laboratory, Central Hospital of Panyu District, 8 Fuyu Dong Road, shiqiao, Guangzhou 511400, Guangdong, P R China;The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510620, China

关键词: Reciprocal regulation;    Small interfering RNA sequences;    Prostate cancer cells;    Prostate cancer gene expression marker 1;    MicroRNA-145;    Long non-coding RNA;   

Others  :  1161145
DOI  :  10.1186/s13046-014-0072-y

 received in 2014-05-23, accepted in 2014-08-25,  发布年份 2014

【 摘 要 】

Prostate cancer gene expression marker 1 (PCGEM1) is a long non-coding RNA (lncRNA) overexpressed in prostate cancer (PCa) cells that promotes PCa initiation and progression, and protects against chemotherapy-induced apoptosis. The microRNA miR-145 functions as a tumor suppressor in PCa. We speculate that reciprocal regulation of PCGEM1 and miR-145 promote proliferation of LNCaP prostate cancer cells. To test this hypothesis, the interaction between PCGEM1 and miR-145 was examined using a luciferase reporter assay. Expression levels were selectively altered in LNCaP cells and noncancerous RWPE-1 prostate cells by transfection of miR-145 or small interfering RNA sequences against (siRNA) PCGEM1. Relative expression levels were detected by RT-PCR, tumor cell growth and early apoptosis by the MTT assay and flow cytometry, respectively, and tumor cell migration and invasion properties by transwell assays. The effect of siRNA PCGEM1 and miR-145 transfection on prostate cancer growth in vivo was examined in the (nu/nu) mouse model. PCGEM1 and miR-145 exhibited reciprocal regulation; downregulation of PCGEM1 expression in LNCaP cells increased expression of miR-145, while overexpression of miR-145 decreased PCGEM1 expression. Transfection of the miR-145 expression vector and siRNA PCGEM1 inhibited tumor cell proliferation, migration, and invasion, and induced early apoptosis both in vitro. In contrast, there was no effect on RWPE-1 cells. We demonstrate a reciprocal negative control relationship between PCGEM1 and miR-145 that regulates both LNCaP cell proliferation and nu/nu PCa tumor growth. The results also identify PCGEM1 and associated regulators as possible targets for PCa therapy.

【 授权许可】

   
2014 He et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Li L, Sun R, Yundan L, Xinmin P, Zhaohui L, Peng B, Xiaofeng Z: Association between polymorphisms in long non-coding RNA PRNCR1 in 8q24 and risk of colorectal cancer. J Exp Clin Cancer Res 2013, 32:104-111. BioMed Central Full Text
• [2]Kotake Y, Nakagawa T, Kitagawa K, Suzuki S, Liu N, Kitagawa M, Xiong Y: Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15INK4B tumor suppressor gene. Oncogene 2010, 30:1956-1962.
• [3]Geisler S, Coller J: RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts. Nat Rev Mol Cell Biol 2013, 14:699-712.
• [4]Ricardo BS, Thaís VP, Elvis TV, Carlos AS, Fernando SR, Hélio RM, Dimas TC, Aparecida MF: Gene expression profile of long non-coding RNA EVF-2 in medulloblastoma cell lines and tissue samples.BMC Proceedings. BioMed Central 2013, 7:61.
• [5]Wierzbicki AT: The role of long non-coding RNA in transcriptional gene silencing. Curr Opin Plant Biol 2012, 15:517-522.
• [6]Gutschner T, Diederichs S: The Hallmarks of Cancer: A long non-coding RNA point of view. RNA Biol 2012, 9:703-719.
• [7]Redis RS, Sieuwerts AM, Look MP, Tudoran O, Ivan C, Spizzo R, Zhang X, de Weerd V, Shimizu M, Ling H, Buiga R, Pop V, Irimie A, Fodde R, Bedrosian I, Martens JW, Foekens JA, Berindan-Neagoe I, Calin GA: CCAT2, a novel long non-coding RNA in breast cancer: expression study and clinical correlations. Oncotarget 2013, 4:1748-1762.
• [8]Ellis BC, Graham LD, Molloy PL: CRNDE, a long non-coding RNA responsive to insulin/IGF signaling, regulates genes involved in central metabolism. Biochim Biophys Acta 1843, 2014:372-386.
• [9]Sado T, Brockdorff N: Advances in understanding chromosome silencing by the long non-coding RNA Xist. Philos Trans R Soc Lond B Biol Sci 2013, 368:20110325.
• [10]Yang F, Bi J, Xue X, Zheng L, Zhi K, Hua J, Fang G: Up-regulated long non-coding RNA H19 contributes to proliferation of gastric cancer cells. FEBS J 2012, 279:3159-3165.
• [11]Chen G, Wang Z, Wang D, Qiu C, Liu M, Chen X, Zhang Q, Yan G, Cui Q: LncRNADisease: a database for long-non-coding RNA-associated diseases. Nucleic Acids Res 2013, 41:D983-D986.
• [12]Liu X, Chen X, Xinfang Y, Tao Y, Bode AM, Zigang D, Ya C: Regulation of microRNAs by epigenetics and their interplay involved in cancer. J Exp Clin Cancer Res 2013, 32:96-104. BioMed Central Full Text
• [13]Png KJ, Yoshida M, Zhang XH, Shu W, Lee H, Rimner A, Chan TA, Comen E, Andrade VP, Kim SW, King TA, Hudis CA, Norton L, Hicks J, Massagué J, Tavazoie SF: MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer. Genes Dev 2011, 25:226-231.
• [14]Leite KR, Tomiyama A, Reis ST, Sousa-Canavez JM, Sañudo A, Camara-Lopes LH, Srougi M: MicroRNA expression profiles in the progression of prostate cancer¿from high-grade prostate intraepithelial neoplasia to metastasis. Urol Oncol 2013, 31:796-801.
• [15]Paraskevopoulou MD, Georgakilas G, Kostoulas N, Reczko M, Maragkakis M, Dalamagas TM, Hatzigeorgiou AG: DIANA-LncBase: experimentally verified and computationally predicted microRNA targets on long non-coding RNAs. Nucleic Acids Res 2013, 41:D239-D245.
• [16]Song SJ, Poliseno L, Song MS, Ala U, Webster K, Ng C, Beringer G, Brikbak NJ, Yuan X, Cantley LC, Richardson AL, Pandolfi PP: MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling. Cell 2013, 154:311-324.
• [17]Yang C, Wang C, Chen X, Chen S, Zhang Y, Zhi F, Wang J, Li L, Zhou X, Li N, Pan H, Zhang J, Zen K, Zhang CY, Zhang C: Identification of seven serum microRNAs from a genome-wide serum microRNA expression profile as potential noninvasive biomarkers for malignant astrocytomas. Int J Cancer 2013, 132:116-127.
• [18]Hajjari M, Behmanesh M, Sadeghizadeh M, Zeinoddini M: Up-regulation of HOTAIR long non-coding RNA in human gastric adenocarcinoma tissues. Med Oncol 2013, 30:670.
• [19]Juan L, Wang G, Radovich M, Schneider BP, Clare SE, Wang Y, Liu Y: Potential roles of microRNAs in regulating long intergenic noncoding RNAs. BMC Med Genomics 2013, 6:S7. BioMed Central Full Text
• [20]Braconi C, Kogure T, Valeri N, Huang N, Nuovo G, Costinean S, Negrini M, Miotto E, Croce CM, Patel T: microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer. Oncogene 2011, 30:4750-4756.
• [21]Augoff K, McCue B, Plow EF, Sossey-Alaoui K: miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer. Mol Cancer 2012, 11:5. BioMed Central Full Text
• [22]Wang J, Liu X, Wu H, Ni P, Gu Z, Qiao Y, Chen N, Sun F, Fan Q: CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer. Nucleic Acids Res 2010, 38:5366-5383.
• [23]Srikantan V, Zou Z, Petrovics G, Xu L, Augustus M, Davis L, Livezey JR, Connell T, Sesterhenn IA, Yoshino K, Buzard GS, Mostofi FK, McLeod DG, Moul JW, Srivastava S: PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer. Proc Natl Acad Sci U S A 2000, 97:12216-12221.
• [24]Petrovics G, Zhang W, Makarem M, Street JP, Connelly R, Sun L, Sesterhenn IA, Srikantan V, Moul JW, Srivastava S: Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients. Oncogene 2004, 23:605-611.
• [25]Srivastava S, Srikantan V, Zou Z, Moul JW: Prostate-specific gene, PCGEM1, and methods of using PCGEM1 to detect, treat, and prevent prostate cancer. 2004, 12:7. U.S. Patent 6,828,4292[P].
• [26]Bao B, Ali S, Banerjee S, Wang Z, Logna F, Azmi AS, Kong D, Ahmad A, Li Y, Padhye S, Sarkar FH: Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Res 2012, 72:335-345.
• [27]Lim L, Balakrishnan A, Huskey N, Jones KD, Jodari M, Ng R, Song G, Riordan J, Anderton B, Cheung ST, Willenbring H, Dupuy A, Chen X, Brown D, Chang AN, Goga A: MicroRNA-494 within an oncogenic microRNA megacluster regulates G1/S transition in liver tumorigenesis through suppression of mutated in colorectal cancer. Hepatology 2014, 59:202-215.
• [28]Hart M, Wach S, Nolte E, Szczyrba J, Menon R, Taubert H, Hartmann A, Stoehr R, Wieland W, Grässer FA, Wullich B: The proto-oncogene ERG is a target of microRNA miR-145 in prostate cancer. FEBS J 2013, 280:2105-2116.
• [29]Jongen-Lavrencic M, Manova-Todorova K, Teruya-Feldstein J, Avigan DE, Delwel R, Pandolfi PP: The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation. Cell Stem Cell 2013, 13:87-101.
• [30]Yamasaki T, Yoshino H, Enokida H, Hidaka H, Chiyomaru T, Nohata N, Kinoshita T, Fuse M, Seki N, Nakagawa M: Novel molecular targets regulated by tumor suppressors microRNA-1 and microRNA-133a in bladder cancer. Int J Oncol 2012, 40:1821-1830.
• [31]Song SJ, Ito K, Ala U, Kats L, Webster K, Sun SM, Jongen-Lavrencic M, Manova-Todorova K, Teruya-Feldstein J, Avigan DE, Delwel R, Pandolfi PP: The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation. Cell Stem Cell 2013, 13:87-101.
• [32]Ozen M, Creighton CJ, Ozdemir M, Ittmann M: Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 2008, 27:1788-1793.
• [33]Chen X, Gong J, Zeng H, Chen N, Huang R, Huang Y, Nie L, Xu M, Xia J, Zhao F, Meng W, Zhou Q: MicroRNA145 targets BNIP3 and suppresses prostate cancer progression. Cancer Res 2010, 70:2728-2738.
• [34]He JH, Li YG, Hang ZP, Wang L, Chun SY, He ML: Analysis biological information for PCGEM1 and speculate the molecular control network express in the prostate cancer. Chin Med Biotechnol 2013, 5:388-391.
• [35]He JH, Li YG, Chen SY, Wang L: Construction of the eukaryotic expression vector targeting hsa-miR-203 and its effects on proliferation and apoptosis of K562 cell lines. Chin J Clin Lab Sci 2012, 30:595-598.
• [36]Ponting CP, Oliver PL, Reik W: Evolution and functions of long noncoding RNAs. Cell 2009, 136:629-641.
• [37]Wilusz JE, Sunwoo H, Spector DL: Long noncoding RNAs: functional surprises from the RNA world. Genes Dev 2009, 23:1494-1504.
• [38]Liu D, Xu B, Chen S, Yang Y, Zhang X, Liu J, Lu K, Zhang L, Liu C, Zhao Y, Jiang H, Liu N, Chen M: Long Non-Coding RNAs and Prostate Cancer. J Nanosci Nanotechnol 2013, 13:3186-3194.
• [39]Ifere GO, Ananaba GA: Prostate cancer gene expression marker 1 (PCGEM1): a patented prostate-specific non-coding gene and regulator of prostate cancer progression. Recent Pat DNA Gene Seq 2009, 3:151-163.
• [40]Kogure T, Yan IK, Lin WL, Patel T: Extracellular Vesicle-Mediated Transfer of a Novel Long Noncoding RNA TUC339: A Mechanism of Intercellular Signaling in Human Hepatocellular Cancer. Genes Cancer 2013, 4:261-272.
• [41]Panzitt K, Tschernatsch MM, Guelly C, Moustafa T, Stradner M, Strohmaier HM, Buck CR, Denk H, Schroeder R, Trauner M, Zatloukal K: Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology 2007, 132:330-342.
• [42]Sun M, Xia R, Jin F, Xu T, Liu Z, De W, Liu X: Downregulated long noncoding RNA MEG3 is associated with poor prognosis and promotes cell proliferation in gastric cancer. Tumor Biol 2013, 12:1-9.
• [43]Guo W, Ren D, Chen X, Tu X, Huang S, Wang M, Song L, Zou X, Peng X: HEF1 promotes epithelial mesenchymal transition and bone invasion in prostate cancer under the regulation of microRNA-145. J Cell Biochem 2013, 114:1606-1615.
• [44]Kojima S, Enokida H, Yoshino H, Itesako T, Chiyomaru T, Kinoshita T, Fuse M, Nishikawa R, Goto Y, Naya Y, Nakagawa M, Seki N: The tumor-suppressive microRNA-143/145 cluster inhibits cell migration and invasion by targeting GOLM1 in prostate cancer. J Hum Genet 2014, 59:78-87.
• [45]Avgeris M, Stravodimos K, Fragoulis EG, Scorilas A: The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients. Br J Cancer 2013, 108:2573-2581.
• [46]Chiyomaru T, Tatarano S, Kawakami K, Enokida H, Yoshino H, Nohata N, Fuse M, Seki N, Nakagawa M: SWAP70, actin?binding protein, function as an oncogene targeting tumor-suppressive miR-145 in prostate cancer. Prostate 2011, 71:1559-1567.
• [47]Fuse M, Nohata N, Kojima S, Sakamoto S, Chiyomaru T, Kawakami K, Enokida H, Nakagawa M, Naya Y, Ichikawa T, Seki N: Restoration of miR-145 expression suppresses cell proliferation, migration and invasion in prostate cancer by targeting FSCN1. Int J Oncol 2011, 38:1093-1101.
• [48]Fu X, Ravindranath L, Tran N, Petrovics G, Srivastava S: Regulation of apoptosis by a prostate-specific and prostate cancer-associated noncoding gene, PCGEM1. DNA Cell Biol 2006, 25:135-141.